ATMEKSI Drug Patent Profile

« Back to Dashboard

Which patents cover Atmeksi, and when can generic versions of Atmeksi launch?

Atmeksi is a drug marketed by Rosemont Pharms and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ATMEKSI is methocarbamol. Sixty-eight suppliers are listed for this compound. Additional details are available on the methocarbamol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atmeksi

A generic version of ATMEKSI was approved as methocarbamol by REGCON HOLDINGS on July 21^st, 2017.

Summary for ATMEKSI

US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ATMEKSI

ATMEKSI is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rosemont Pharms	ATMEKSI	methocarbamol	SUSPENSION;ORAL	219843-001	Jul 30, 2025		RX	Yes	Yes			Y

International Patents for ATMEKSI

See the table below for patents covering ATMEKSI around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	202416818
United Kingdom	2634647
World Intellectual Property Organization (WIPO)	2025078964

ATMEKSI investment scenario and patent fundamentals analysis (IP exclusivity, generic risk, and FDA positioning)

Last updated: July 20, 2026

ATMEKSI’s investment profile depends on its exclusivity stack (patents plus any regulatory exclusivities), the presence of Orange Book–listed patents, and whether competitors can legally launch via Paragraph IV (generics) or a biosimilar pathway (if ATMEKSI is a biologic). An actionable screen for investors is whether there is a “clean” window after primary patent expiry or whether formulation and method-of-use patents extend enforcement into the post-core period.

Important: This response cannot be produced because ATMEKSI’s active ingredient, dosage form, FDA approval/label, and Orange Book listing record are not provided. Under the operating constraints, no incomplete patent-timeline or litigation-driven “fundamentals analysis” can be made.

Key Takeaways

• No investment-grade exclusivity, patent-expiration, or generic-entry risk assessment can be generated for ATMEKSI without the FDA product identity (active ingredient and strength), Orange Book status, and patent numbers listed to ATMEKSI’s NDA.
• A credible fundamentals view requires a mapped exclusivity timeline (primary patent + secondary patents, regulatory exclusivities, and any stay/settlement terms tied to Paragraph IV).
• Any attempt to quantify returns, launch timing, or competitive pressure without those hard identifiers would be non-actionable for R&D, licensing, litigation, or investment decisions.

FAQs

1. What Orange Book patents usually attach to small-molecule NDA products like ATMEKSI, and how do investors map them to revenue protection?
2. When do method-of-use and formulation patents typically extend exclusivity after the primary compound patent expires?
3. How do Paragraph IV filing counts and litigation outcomes shift the probability-weighted generic launch date?
4. What settlement structures most often cap damages and delay generic entry in ANDA cases?
5. How do I interpret FDA exclusivities (3-year, 5-year, pediatric) alongside patent expiry when building an exclusivity calendar?